Tesamorelin: The GHRH Analog and What the Research Actually Shows
Tesamorelin is one of the few peptides of its kind to earn regulatory approval. Here is the scientific review — how the GHRH mechanism works, what the clinical trials showed, and where the line sits between approved use and the grey market.
What is tesamorelin?
Tesamorelin (brand name Egrifta) is a synthetic analog of growth-hormone-releasing hormone (GHRH). It stimulates the pituitary gland to secrete growth hormone (GH) in a physiological manner. The FDA approved it to reduce excess visceral abdominal fat (lipodystrophy) in people with HIV. Outside that indication it has been studied but is not approved, and unsupervised use carries risks.
How tesamorelin works
Unlike injecting growth hormone directly, tesamorelin works "upstream": it is a GHRH analog that stimulates the pituitary gland to secrete growth hormone in a way closer to the body's natural physiological rhythm.
The idea is that by preserving the natural regulatory mechanism (including feedback loops), growth hormone and IGF-1 levels can be raised in a more controlled manner than with direct external GH administration.
What the clinical trials showed
- Controlled trials showed a significant reduction in visceral adipose tissue in HIV patients with lipodystrophy.
- An increase in IGF-1 levels was observed — a marker of growth hormone activity.
- The effect on visceral fat tended to reverse after stopping treatment.
- The strongest evidence is focused on the specific approved indication, not on general use for body recomposition or "anti-aging".
Regulatory status
Tesamorelin was approved by the FDA under the name Egrifta for a very specific indication: reducing excess visceral fat in HIV patients with lipodystrophy. It is not a drug for general weight loss or "toning".
Outside the approved indication, any use is considered off-label or investigational. Availability and regulatory status vary between countries — verify against your physician and the official label.
Safety and side effects
Reported side effects include injection-site reactions, joint pain, edema, and changes in insulin sensitivity. Raising growth hormone levels is not risk-free and requires monitoring.
Tesamorelin is not suitable for everyone, and particular caution applies in certain conditions (including diabetes and cancer risk). Use requires evaluation and follow-up by a qualified physician.
Warning: grey market and "research-only" peptides
Tesamorelin is sometimes sold as a "research-only" powder on unregulated sites, often for uses other than the approved indication. These carry serious risks: unknown purity, incorrect dosing, contamination, and lack of medical supervision.
The efficacy and safety data from the trials apply only to the regulated compound given under medical supervision. PepVero does not sell or supply any compounds and presents this information for educational purposes only.
The strongest evidence for tesamorelin is focused on reducing visceral fat in HIV patients — the FDA-approved indication.
Frequently asked questions
What is tesamorelin used for?
Tesamorelin (Egrifta) was approved by the FDA to reduce excess visceral fat in HIV patients with lipodystrophy. It is not a drug for general weight loss or "toning".
How is tesamorelin different from injecting growth hormone?
Tesamorelin is a GHRH analog that stimulates the body to secrete growth hormone physiologically, instead of injecting external GH directly. The idea is to preserve the natural regulatory mechanism.
Is tesamorelin safe for body recomposition or anti-aging?
There is no strong evidence supporting such use, and it is not approved for these purposes. Raising growth hormone carries risks and requires medical follow-up. Off-label use is not recommended without supervision.
What are the side effects?
Reported side effects include injection-site reactions, joint pain, edema, and changes in insulin sensitivity. Caution is needed in certain conditions. Use requires medical evaluation and monitoring.
Can you buy tesamorelin online?
Do not purchase from unregulated sources. "Research-only" powders carry risks of purity, contamination, and incorrect dosing, and the trial safety data do not apply to them.
Sources
This page is for educational and research information only and is not medical advice, diagnosis, or a recommendation to obtain or use any compound. Tesamorelin is approved for a specific indication only and requires medical supervision. Do not obtain or use unregulated peptides. Consult a qualified physician.
Go deeper into the data
Browse the peptide database, read the safety guide, and explore our evidence-scoring methodology.